NASDAQ:TIL - Instil Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.00
  • Forecasted Upside: 152.74 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$11.87
▼ -1.54 (-11.48%)

This chart shows the closing price for TIL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Instil Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TIL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TIL

Analyst Price Target is $30.00
▲ +152.74% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Instil Bio in the last 3 months. The average price target is $30.00, with a high forecast of $34.00 and a low forecast of $23.00. The average price target represents a 152.74% upside from the last price of $11.87.

This chart shows the closing price for TIL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Instil Bio.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/12/2021Robert W. BairdInitiated CoverageOutperform$34.00N/A
5/26/2021Morgan StanleyLower Price TargetEqual Weight$24.00 ➝ $23.00N/A
4/19/2021Truist FinancialInitiated CoverageBuy$32.00N/A
4/19/2021CowenInitiated CoverageOutperformN/A
4/19/2021Morgan StanleyInitiated CoverageEqual Weight$24.00N/A
4/19/2021Jefferies Financial GroupInitiated CoverageBuy$31.00N/A
4/13/2021Truist FinancialInitiated CoverageBuy$32.00N/A
4/13/2021Jefferies Financial GroupInitiated CoverageBuy$31.00N/A
4/13/2021Morgan StanleyInitiated CoverageEqual Weight$24.00N/A
4/13/2021CowenInitiated CoverageOutperformN/A
(Data available from 1/26/2017 forward)

News Sentiment Rating

0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Instil Bio logo
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Read More

Today's Range

Now: $11.87
Low: $11.70
High: $13.61

50 Day Range

MA: $17.33
Low: $11.87
High: $22.33

52 Week Range

Now: $11.87
Low: $11.43
High: $29.49

Volume

445,176 shs

Average Volume

356,949 shs

Market Capitalization

$1.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Instil Bio?

The following sell-side analysts have issued reports on Instil Bio in the last year: Cowen Inc, Jefferies Financial Group Inc., Morgan Stanley, Robert W. Baird, Truist Financial Co., and Zacks Investment Research.
View the latest analyst ratings for TIL.

What is the current price target for Instil Bio?

4 Wall Street analysts have set twelve-month price targets for Instil Bio in the last year. Their average twelve-month price target is $30.00, suggesting a possible upside of 148.3%. Robert W. Baird has the highest price target set, predicting TIL will reach $34.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $23.00 for Instil Bio in the next year.
View the latest price targets for TIL.

What is the current consensus analyst rating for Instil Bio?

Instil Bio currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TIL will outperform the market and that investors should add to their positions of Instil Bio.
View the latest ratings for TIL.

How do I contact Instil Bio's investor relations team?

Instil Bio's physical mailing address is CONTINENTAL BUILDING 25 CHURCH STREET, HAMILTON D0, HM1Z. The company's listed phone number is 240-676-3715 and its investor relations email address is [email protected] The official website for Instil Bio is www.tillcap.com.